BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 15854468)

  • 21. BCR/ABL mRNA targeting small interfering RNA effects on proliferation and apoptosis in chronic myeloid leukemia.
    Zhu XS; Lin ZY; Du J; Cao GX; Liu G
    Asian Pac J Cancer Prev; 2014; 15(12):4773-80. PubMed ID: 24998540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
    Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study on the treatment of the p15 gene combined with Bcr-abl-specific siRNA and STI571 for chronic myeloid leukemia.
    Wang W; Du Y; Li NN; Lv FF; Lin GQ
    Genet Mol Res; 2014 May; 13(2):4089-101. PubMed ID: 24938701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
    Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effects of Her-2/neu siRNA-mediated gene silencing on cell cycle and apoptosis of lung adenocarcinoma cells].
    Ren SH; Wang JW; Zhang L
    Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(22):1530-4. PubMed ID: 16179111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
    Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
    Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Knockdown of Hsp701A induces K562 cells apoptosis by RNA interference].
    Zhu Q; Zhang WG; Wang LF; Wang F; Zhang Y; Yang AG
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Jul; 22(4):480-2, 484. PubMed ID: 16806014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of hydroxyurea combined with interferon-alpha on growth and apoptosis-related oncogene expression of K562 cells].
    Chen H; Luo Z; Luo S
    Zhonghua Yi Xue Za Zhi; 2000 Aug; 80(8):606-9. PubMed ID: 11798827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi).
    Wilda M; Fuchs U; Wössmann W; Borkhardt A
    Oncogene; 2002 Aug; 21(37):5716-24. PubMed ID: 12173041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells.
    Arthanari Y; Pluen A; Rajendran R; Aojula H; Demonacos C
    J Control Release; 2010 Aug; 145(3):272-80. PubMed ID: 20403398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Specific inhibition of HER-2 expression in ovarian carcinoma cells by siRNA targeting HER-2].
    Lu YM; Zhang SL; Meng LR; Zhao YY
    Zhonghua Yi Xue Za Zhi; 2006 Mar; 86(9):619-23. PubMed ID: 16681908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Impact of RNA interference targeting hypoxia-inducible factor-1alpha on chemosensitivity in esophageal squamous cell carcinoma cells under hypoxia].
    Wu XA; Sun Y; Fan QX; Wang LX; Wang RL; Zhang L
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(37):2640-4. PubMed ID: 18162154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells.
    Dou QP; McGuire TF; Peng Y; An B
    J Pharmacol Exp Ther; 1999 May; 289(2):781-90. PubMed ID: 10215653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Study on mismatch repair genes of chronic myeloid leukemia].
    Luo J; Peng ZG; Chen Y; Lai YR; Lu YY; Song SJ
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):103-6. PubMed ID: 16732964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Synergism of As2S2 and STI 571 in inducing apoptosis of K562 cells].
    Li JE; Sun GL; Wu YL; Wu WL
    Zhonghua Xue Ye Xue Za Zhi; 2003 Nov; 24(11):580-3. PubMed ID: 14720443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
    Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The effect of multi-unit ribozymes on the growth inhibition and apoptosis induction of CML K562 cells].
    Feng Q; Sun B; Sun K; Shang Z; Wang S; Wang W; Zhao Y; Yan Z; Han W; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):435-9. PubMed ID: 12485492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
    Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
    Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.